Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 2/20 | 0.37 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20437909 | 0.83 | NOTUM (0.58) | NOTUMKEAP1CYP19A1USP1WDR48 | |
| SCHEMBL20444416 | 0.81 | NOTUM (0.57) | NOTUMKEAP1CYP19A1USP1WDR48 | |
| SCHEMBL26918079 | 0.78 | NOTUM (0.57) | NOTUMKEAP1CYP19A1USP1WDR48 | |
| SCHEMBL22214068 | 0.78 | LMNA (0.46) | NOTUMTRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL13122736 | 0.78 | NOTUM (0.63) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL25428051 | 0.76 | NOTUM (0.42) | NOTUMLMNA | |
| SCHEMBL5612825 | 0.76 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL22325390 | 0.76 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL4564455 | 0.76 | NOTUM (0.58) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL25065202 | 0.75 | NOTUM (0.53) | NOTUMKEAP1LMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | NOTUM 4432/4885KEAP1 2391/4885TRPA1 4510/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | NOTUM 4496/4885KEAP1 2003/4885TRPA1 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.